Effectiveness of a rehabilitative programme in improving fatigue and function in rheumatoid arthritis patients treated with biologics: a pilot study

被引:0
|
作者
Di Gioia, L. [1 ]
Zincarelli, C. [1 ]
Di Minno, M. N. D. [2 ]
Rengo, G. [3 ]
Peluso, R. [4 ]
Spano, A. [4 ]
Iervolino, S. [1 ]
Pappone, N. [1 ]
机构
[1] Salvatore Maugeri Fdn IRCCS Sci Inst, Rheumatol & Rehabil Res Unit, Telese Terme, BN, Italy
[2] Univ Naples Federico II, Reference Ctr Coagulat Disorders, Dept Clin & Expt Med, Naples, Italy
[3] Salvatore Maugeri Fdn IRCCS Sci Inst, Dept Cardiol, Telese Terme, BN, Italy
[4] Univ Naples Federico II, Rheumatol Res Unit, Dept Clin & Expt Med, Naples, Italy
关键词
rheumatoid arthritis; fatigue; rehabilitation; functional class; CARDIOVASCULAR RISK; EXERCISE; WOMEN; PAIN; FIBROMYALGIA; ASSOCIATION; EFFICACY; THERAPY; FITNESS; DISEASE;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To evaluate the effectiveness of a personalised rehabilitative programme in improving fatigue and function in rheumatoid arthritis (RA) female patients treated with biologic DMARDs. Methods. Thirty-eight consecutive female RA in-patients treated with biologics, entered this prospective pilot study. All subjects were in high disease activity (DAS-28>5.1). After baseline (T0) evaluation, a personalised 4-weeks rehabilitative programme was added to standard biologic treatment and all patients were re-evaluated at the end of the rehabilitative treatment (T1), at 3 (T2), 6 (T3) and 9 (T4) month follow-up. Clinical rheumatologic assessment included the DAS-28, TJC, SJC, global health status, HAQ and FACIT. Results. Subjects showed a mean age of 65 +/- 3.5 years and a 10 +/- 1,1 years mean disease duration. All clinical and laboratory outcomes significantly improved at the different follow-up times as compared to baseline. In particular, a significant improvement in function and fatigue indices (HAQ and FACIT) was found since T1 to T4 as compared to TO. During the follow-up, DAS-28 decreased. Accordingly, about 30% of subjects achieved a moderate disease activity (DAS-28<5.1). Conclusion. A combined treatment biologics-rehabilitation is effective in improving function and fatigue in female patients with established RA. Fatigue results independent from disease activity.
引用
收藏
页码:285 / 288
页数:4
相关论文
共 50 条
  • [21] Analysis of Shoulder Joint Destruction in Rheumatoid Arthritis Patients Treated with Biologics.
    Yonemoto, Yukio
    Okamura, Koichi
    Kaneko, Tetsuya
    Okura, Chisa
    Takagishi, Kenji
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S223 - S223
  • [22] Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics
    Kengo Takahashi
    Takao Setoguchi
    Hiroki Tawaratsumida
    Yoshiya Arishima
    Hiroyuki Tominaga
    Yasuhiro Ishidou
    Satoshi Nagano
    Sanae Shigemizu
    Noriko Aoki
    Masaki Akimoto
    Hideo Otsubo
    Takemasa Matsuda
    Hironori Kakoi
    Toshihiko Izumi
    Shunsuke Nakamura
    Masahiro Yokouchi
    Nobuhiko Sunahara
    Setsuro Komiya
    BMC Musculoskeletal Disorders, 16
  • [23] Effectiveness of Rituximab in Patients with Rheumatoid Arthritis: Observational Study from the British Society for Rheumatology Biologics Register
    Soliman, Moetaza M.
    Hyrich, Kimme L.
    Lunt, Mark
    Watson, Kath D.
    Symmons, Deborah P. M.
    Ashcroft, Darren M.
    JOURNAL OF RHEUMATOLOGY, 2012, 39 (02) : 240 - 246
  • [24] Comparative Risk of Diabetes Mellitus in Rheumatoid Arthritis Patients Treated with Different Biologics- a Cohort Study
    Desai, Rishi J.
    Dejene, Sara
    Jin, Yinzhu
    Liu, Jun
    Kim, Seoyoung C.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [25] Predictive factors related to shoulder joint destruction in rheumatoid arthritis patients treated with biologics: A prospective study
    Yonemoto, Yukio
    Okamura, Koichi
    Kobayashi, Tsutomu
    Kaneko, Tetsuya
    Okura, Chisa
    Suto, Takahito
    Tachibana, Masahiro
    Tsushima, Yoshito
    Takagishi, Kenji
    MODERN RHEUMATOLOGY, 2017, 27 (04) : 587 - 592
  • [26] Improving medication adherence in rheumatoid arthritis (RA): a pilot study
    Ferguson, A.
    Ibrahim, F. A.
    Thomas, V.
    Weinman, J.
    Simpson, C.
    Cope, A. P.
    Scott, D. L.
    Lempp, H.
    PSYCHOLOGY HEALTH & MEDICINE, 2015, 20 (07) : 781 - 789
  • [27] Immune function in patients with rheumatoid arthritis treated with etanercept
    Moreland, LW
    Bucy, RP
    Weinblatt, ME
    Mohler, KM
    Spencer-Green, GT
    Chatham, WW
    CLINICAL IMMUNOLOGY, 2002, 103 (01) : 13 - 21
  • [28] Comparative effectiveness of biologics in patients with rheumatoid arthritis stratified by body mass index: a cohort study in a Swiss registry
    Vallejo-Yague, Enriqueta
    Burkard, Theresa
    Finckh, Axel
    Burden, Andrea Michelle
    BMJ OPEN, 2024, 14 (02):
  • [29] Comparison of the outcomes of Pneumocystis jirovecii pneumonia in rheumatoid arthritis patients treated with and without biologics
    Ohmura, Shin-ichiro
    Matsui, Hiroki
    Miyamoto, Toshiaki
    Shichi, Daisuke
    Masui, Takayuki
    Ichijo, Katsutoshi
    Homma, Yuya
    Fujioka, Haruka
    Nagai, Tatsuya
    Nakashima, Kei
    RESPIRATORY INVESTIGATION, 2024, 62 (03) : 377 - 383
  • [30] RHEUMATOID ARTHRITIS (RA) TREATMENT COSTS AMONG US PATIENTS TREATED WITH INFUSED BIOLOGICS
    Ogale, S.
    Henk, H. J.
    VALUE IN HEALTH, 2010, 13 (03) : A125 - A126